These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 34684404)

  • 21. Baseline homeostasis model assessment of insulin resistance associated with fibrosis progression in patients with nonalcoholic fatty liver disease without diabetes: A cohort study.
    Koo DJ; Lee MY; Jung I; Moon SJ; Kwon H; Park SE; Rhee EJ; Lee WY
    PLoS One; 2021; 16(8):e0255535. PubMed ID: 34432804
    [TBL] [Abstract][Full Text] [Related]  

  • 22. IMPACT OF TYPE 2 DIABETES ON NONALCOHOLIC STEATOHEPATITIS AND ADVANCED FIBROSIS IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE.
    Bian H; Zhu X; Xia M; Yan H; Chang X; Hu X; Pan B; Guo W; Li X; Gao X
    Endocr Pract; 2020 Apr; 26(4):444-453. PubMed ID: 31968197
    [No Abstract]   [Full Text] [Related]  

  • 23. Lower eGFR is associated with increased probability of liver fibrosis in Chinese diabetic patients.
    Wang Y; Yu Y; Wan H; Chen Y; Xia F; Zhang W; Zhang K; Gu X; Zhang Y; Lin Z; Yu Y; Wang N; Lu Y
    Diabetes Metab Res Rev; 2020 Jul; 36(5):e3294. PubMed ID: 32017389
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Significant fibrosis predicts new-onset diabetes mellitus and arterial hypertension in patients with NASH.
    Ampuero J; Aller R; Gallego-Durán R; Crespo J; Calleja JL; García-Monzón C; Gómez-Camarero J; Caballería J; Lo Iacono O; Ibañez L; García-Samaniego J; Albillos A; Francés R; Fernández-Rodríguez C; Diago M; Soriano G; Andrade RJ; Latorre R; Jorquera F; Morillas RM; Escudero D; Estévez P; Guerra MH; Augustín S; Banales JM; Aspichueta P; Benlloch S; Rosales JM; Salmerón J; Turnes J; Romero Gómez M;
    J Hepatol; 2020 Jul; 73(1):17-25. PubMed ID: 32147361
    [TBL] [Abstract][Full Text] [Related]  

  • 25. NAFLD fibrosis score: a prognostic predictor for mortality and liver complications among NAFLD patients.
    Treeprasertsuk S; Björnsson E; Enders F; Suwanwalaikorn S; Lindor KD
    World J Gastroenterol; 2013 Feb; 19(8):1219-29. PubMed ID: 23482703
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cohort study of non-alcoholic fatty liver disease, NAFLD fibrosis score, and the risk of incident diabetes in a Korean population.
    Chang Y; Jung HS; Yun KE; Cho J; Cho YK; Ryu S
    Am J Gastroenterol; 2013 Dec; 108(12):1861-8. PubMed ID: 24100261
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Histopathological differences in patients with biopsy-proven non-alcoholic fatty liver disease with and without type 2 diabetes.
    Aller de la Fuente R; Mora Cuadrado N; Tafur C; López Gómez JJ; Gómez de la Cuesta S; García Sánchez MC; Antolin Melero B; de Luis Román DA
    Endocrinol Diabetes Nutr (Engl Ed); 2018; 65(6):354-360. PubMed ID: 29477355
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Liver and Cardiovascular Damage in Patients With Lean Nonalcoholic Fatty Liver Disease, and Association With Visceral Obesity.
    Fracanzani AL; Petta S; Lombardi R; Pisano G; Russello M; Consonni D; Di Marco V; Cammà C; Mensi L; Dongiovanni P; Valenti L; Craxì A; Fargion S
    Clin Gastroenterol Hepatol; 2017 Oct; 15(10):1604-1611.e1. PubMed ID: 28554682
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prevalence of Nonalcoholic Steatohepatitis-Associated Cirrhosis in the United States: An Analysis of National Health and Nutrition Examination Survey Data.
    Kabbany MN; Conjeevaram Selvakumar PK; Watt K; Lopez R; Akras Z; Zein N; Carey W; Alkhouri N
    Am J Gastroenterol; 2017 Apr; 112(4):581-587. PubMed ID: 28195177
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Association of low skeletal muscle mass with advanced liver fibrosis in patients with non-alcoholic fatty liver disease.
    Kang MK; Park JG; Lee HJ; Kim MC
    J Gastroenterol Hepatol; 2019 Sep; 34(9):1633-1640. PubMed ID: 30667551
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Analysis of metabolic risk factors for developing nonalcoholic fatty liver in patients with type 2 diabetes mellitus].
    Guo M; Xi G; Yang N; Yao H
    Zhonghua Gan Zang Bing Za Zhi; 2014 Aug; 22(8):631-5. PubMed ID: 25243967
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Association between Atrial Fibrillation and Advanced Liver Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease.
    Kang MK; Park JG; Kim MC
    Yonsei Med J; 2020 Oct; 61(10):860-867. PubMed ID: 32975060
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Association between diabetes, family history of diabetes, and risk of nonalcoholic steatohepatitis and fibrosis.
    Loomba R; Abraham M; Unalp A; Wilson L; Lavine J; Doo E; Bass NM;
    Hepatology; 2012 Sep; 56(3):943-51. PubMed ID: 22505194
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Advanced fibrosis associates with atherosclerosis in subjects with nonalcoholic fatty liver disease.
    Chen Y; Xu M; Wang T; Sun J; Sun W; Xu B; Huang X; Xu Y; Lu J; Li X; Wang W; Bi Y; Ning G
    Atherosclerosis; 2015 Jul; 241(1):145-50. PubMed ID: 25988358
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical Model for NASH and Advanced Fibrosis in Adult Patients With Diabetes and NAFLD: Guidelines for Referral in NAFLD.
    Bazick J; Donithan M; Neuschwander-Tetri BA; Kleiner D; Brunt EM; Wilson L; Doo E; Lavine J; Tonascia J; Loomba R
    Diabetes Care; 2015 Jul; 38(7):1347-55. PubMed ID: 25887357
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Moderate alcohol consumption is associated with advanced fibrosis in non-alcoholic fatty liver disease and shows a synergistic effect with type 2 diabetes mellitus.
    Blomdahl J; Nasr P; Ekstedt M; Kechagias S
    Metabolism; 2021 Feb; 115():154439. PubMed ID: 33246008
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lumican in Obese Patients with Nonalcoholic Fatty Liver Disease With or Without Prediabetes.
    Karamfilova V; Gateva A; Assyov Y; Nedeva I; Velikova T; Cherkezov N; Mateva L; Kamenov Z
    Metab Syndr Relat Disord; 2020 Nov; 18(9):443-448. PubMed ID: 32780624
    [No Abstract]   [Full Text] [Related]  

  • 38. Development and Validation of Hepamet Fibrosis Scoring System-A Simple, Noninvasive Test to Identify Patients With Nonalcoholic Fatty Liver Disease With Advanced Fibrosis.
    Ampuero J; Pais R; Aller R; Gallego-Durán R; Crespo J; García-Monzón C; Boursier J; Vilar E; Petta S; Zheng MH; Escudero D; Calleja JL; Aspichueta P; Diago M; Rosales JM; Caballería J; Gómez-Camarero J; Lo Iacono O; Benlloch S; Albillos A; Turnes J; Banales JM; Ratziu V; Romero-Gómez M;
    Clin Gastroenterol Hepatol; 2020 Jan; 18(1):216-225.e5. PubMed ID: 31195161
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Association of glycated hemoglobin with the risk of advanced fibrosis in non-alcoholic fatty liver disease patients without diabetes.
    Yu C; Wang L; Xue H; Lin H; Li Y; Chan SO
    Clin Res Hepatol Gastroenterol; 2019 Feb; 43(1):58-66. PubMed ID: 30274911
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Risk of severe illness of COVID-19 patients with NAFLD and increased NAFLD fibrosis scores.
    Yao R; Zhu L; Wang J; Liu J; Xue R; Xue L; Liu L; Li C; Zhao H; Cheng J; Huang S; Li Y; Zhao XA; Zhu C; Li M; Huang R; Wu C
    J Clin Lab Anal; 2021 Aug; 35(8):e23880. PubMed ID: 34213039
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.